brl-50481 brl-50481 brl-50481 is a drug developed by glaxosmithkline which is the first compound that acts as a phosphodiesterase inhibitor selective for the pde7 family. pde7 activity is encoded by two genes, pde7a and pde7b. brl-50481 actually shows about an 80-fold preference for the pde7a subtype, for which it was developed, over pde7b. brl-50481 has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for pde7 inhibitors in the treatment of osteoporosis. brl-50481clinical dataatc codenoneidentifiers iupac name n,n,2-trimethyl-5-nitrobenzenesulfonamide cas number433695-36-4 ypubchem cid2921148iuphar/bps5154chemspider2194720 nunii03g869pr3pchebichebi:93472chemblchembl484928 ncomptox dashboard (epa)dtxsid30195832 chemical and physical dataformulac9h12n2o4smolar mass244.27 g·mol−13d model (jsmol)interactive image smiles cc1ccc(n(=o)=o)cc1s(=o)(=o)n(c)c inchi inchi=1s/c9h12n2o4s/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6h,1-3h3 nkey:ifiufcjflgcqph-uhfffaoysa-n n ny (what is this?) (verify)